KNSA Kiniksa (KNSA) Q1 FY26 earnings call
Kiniksa delivered strong Q1 FY26 results, driven by robust ARCALYST commercial execution and a significant increase in new patient enrollments and prescribers. The company raised its full-year revenue guidance and remains cash flow positive, enabling continued investment in its clinical pipeline, including KPL-387 and KPL-1161, with key milestones expected later this year. Management is focused on expanding market penetration for ARCALYST through targeted commercial strategies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
KNSA operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Prescribers | 4,150+At the end of 2025, more than 4,150 prescribers had written a prescription for ARCALYST.Source: earnings call transcript | — | 5,000+Approximately 450 additional health care professionals wrote their first ARCALYST prescription in the second quarter, bringing the total prescriber base to more than 5,000 launch to date.Source: earnings call transcript | — |
| Repeat prescribers | 1,200+Of those, around 29% or more than 1,200 prescribers have written ARCALYST for 2 or more recurrent pericarditis patients.Source: earnings call transcript | ~1,320We also saw growth in the number of health care professionals who became repeat prescribers during Q1, resulting in approximately 1,320 prescribers in total who have now prescribed ARCALYST multiple times.Source: earnings call transcript | — | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.